Decongestion strategies and renin-angiotensin-aldosterone system activation in acute heart failure

JACC: Heart Failure

Volumn 3, Issue 2, 2015, Pages 97-107

  Mentz, Robert J ^a   Stevens, Susanna R ^a   DeVore, Adam D ^a   Lala, Anuradha ^b,c   Vader, Justin M ^d   AbouEzzeddine, Omar F ^e   Khazanie, Prateeti ^a   Redfield, Margaret M ^e   Stevenson, Lynne W ^b   O'Connor, Christopher M ^a   Goldsmith, Steven R ^f   Bart, Bradley A ^f   Anstrom, Kevin J ^a   Hernandez, Adrian F ^a   Braunwald, Eugene ^b   Felker, G Michael ^a  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e MAYO CLINIC   (United States)

^f HENNEPIN COUNTY MEDICAL CENTER   (United States)

Author keywords

Acute heart failure; Cardiorenal syndrome; Decongestion; Diuretics; Outcomes; RAAS activation; Ultrafiltration

Indexed keywords

ALDOSTERONE; ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIOLOGICAL MARKER; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FUROSEMIDE; HYDRALAZINE; LOOP DIURETIC AGENT; NITRIC ACID DERIVATIVE; RENIN; SODIUM; UREA; DIURETIC AGENT;

ACUTE HEART FAILURE; ADULT; AGED; ARTICLE; BLOOD PRESSURE MEASUREMENT; COHORT ANALYSIS; CONTINUOUS INFUSION; CONTROLLED STUDY; DEATH; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG MEGADOSE; FEMALE; HAZARD RATIO; HOSPITALIZATION; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PLASMA RENIN ACTIVITY; POPULATION RESEARCH; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SODIUM BLOOD LEVEL; TREATMENT OUTCOME; ULTRAFILTRATION; UREA NITROGEN BLOOD LEVEL; BLOOD; BLOOD PRESSURE; DOSE RESPONSE; DRUG ADMINISTRATION; HEART FAILURE; HEMOFILTRATION; INTRAVENOUS DRUG ADMINISTRATION;

AGED; ALDOSTERONE; BIOMARKERS; BLOOD PRESSURE; BLOOD UREA NITROGEN; DIURETICS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FUROSEMIDE; HEART FAILURE; HEMOFILTRATION; HUMANS; INFUSIONS, INTRAVENOUS; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; RENIN; RENIN-ANGIOTENSIN SYSTEM; SODIUM;

EID: 84959935667     PISSN: 22131779     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jchf.2014.09.003     Document Type: Article

References (24)

1. Braunwald E. Heart failure. JAm Coll Cardiol HF 2013, 1:1-20.
2. Givertz M.M. Manipulation of the renin-angiotensin system. Circulation 2001, 104:E14-E18.
3. Marenzi G., Grazi S., Giraldi F., et al. Interrelation of humoral factors, hemodynamics, and fluid and salt metabolism in congestive heart failure: effects of extracorporeal ultrafiltration. Am J Med 1993, 94:49-56.
4. Agostoni P., Marenzi G., Lauri G., et al. Sustained improvement in functional capacity after removal of body fluid with isolated ultrafiltration in chronic cardiac insufficiency: Failure of furosemide to provide the same result. Am J Med 1994, 96:191-199.
5. Felker G.M., O'Connor C.M., Braunwald E. Loop diuretics in acute decompensated heart failure: Necessary? Evil? A necessary evil?. Circ Heart Fail 2009, 2:56-62.
6. Felker G.M., Mentz R.J. Diuretics and ultrafiltration in acute decompensated heart failure. JAm Coll Cardiol 2012, 59:2145-2153.
7. Domanski M., Norman J., Pitt B., Haigney M., Hanlon S., Peyster E. Diuretic use, progressive heart failure, and death in patients in the Studies Of Left Ventricular Dysfunction (SOLVD). JAm Coll Cardiol 2003, 42:705-708.
8. Hasselblad V., Gattis Stough W., Shah M.R., et al. Relation between dose of loop diuretics and outcomes in a heart failure population: results of the ESCAPE trial. Eur J Heart Fail 2007, 9:1064-1069.
9. Shah R.V., McNulty S., O'Connor C.M., Felker G.M., Braunwald E., Givertz M.M. Effect of admission oral diuretic dose on response to continuous versus bolus intravenous diuretics in acute heart failure: an analysis from diuretic optimization strategies in acute heart failure. Am Heart J 2012, 164:862-868.
10. Francis G.S., Siegel R.M., Goldsmith S.R., Olivari M.T., Levine T.B., Cohn J.N. Acute vasoconstrictor response to intravenous furosemide in patients with chronic congestive heart failure. Activation of the neurohumoral axis. Ann Intern Med 1985, 103:1-6.
11. Francis G.S., Benedict C., Johnstone D.E., et al. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the studies of left ventricular dysfunction (SOLVD). Circulation 1990, 82:1724-1729.
12. Ronco C., Cicoira M., McCullough P.A. Cardiorenal syndrome type 1: pathophysiological crosstalk leading to combined heart and kidney dysfunction in the setting of acutely decompensated heart failure. JAm Coll Cardiol 2012, 60:1031-1042.
13. Felker G.M., Lee K.L., Bull D.A., et al. Diuretic strategies in patients with acute decompensated heart failure. NEngl J Med 2011, 364:797-805.
14. Bart B.A., Goldsmith S.R., Lee K.L., et al. Cardiorenal rescue study in acute decompensated heart failure: rationale and design of CARRESS-HF, for the heart failure clinical research network. JCard Fail 2012, 18:176-182.
15. Bart B.A., Goldsmith S.R., Lee K.L., et al. Ultrafiltration in decompensated heart failure with cardiorenal syndrome. NEngl J Med 2012, 367:2296-2304.
16. Bayliss J., Norell M., Canepa-Anson R., Sutton G., Poole-Wilson P. Untreated heart failure: clinical and neuroendocrine effects of introducing diuretics. Br Heart J 1987, 57:17-22.
17. Cataliotti A., Boerrigter G., Costello-Boerrigter L.C., et al. Brain natriuretic peptide enhances renal actions of furosemide and suppresses furosemide-induced aldosterone activation in experimental heart failure. Circulation 2004, 109:1680-1685.
18. Hori Y., Ohshima N., Kanai K., Hoshi F., Itoh N., Higuchi S. Differences in the duration of diuretic effects and impact on the renin-angiotensin-aldosterone system of furosemide in healthy dogs. JVet Med Sci 2010, 72:13-18.
19. McCurley J.M., Hanlon S.U., Wei S.K., Wedam E.F., Michalski M., Haigney M.C. Furosemide and the progression of left ventricular dysfunction in experimental heart failure. JAm Coll Cardiol 2004, 44:1301-1307.
20. Giglioli C., Landi D., Cecchi E., et al. Effects of ultrafiltration vs. diuretics on clinical, biohumoral and haemodynamic variables in patients with decompensated heart failure: the ULTRADISCO study. Eur J Heart Fail 2011, 13:337-346.
21. Ambrosy A.P., Pang P.S., Khan S., et al. Clinical course and predictive value of congestion during hospitalization in patients admitted for worsening signs and symptoms of heart failure with reduced ejection fraction: findings from the EVEREST trial. Eur Heart J 2013, 34:835-843.
22. Nohria A., Hasselblad V., Stebbins A., et al. Cardiorenal interactions: insights from the ESCAPE trial. JAm Coll Cardiol 2008, 51:1268-1274.
23. Mullens W., Abrahams Z., Francis G.S., et al. Importance of venous congestion for worsening of renal function in advanced decompensated heart failure. JAm Coll Cardiol 2009, 53:589-596.
24. Swedberg K., Eneroth P., Kjekshus J., Snapinn S. Effects of enalapril and neuroendocrine activation on prognosis in severe congestive heart failure (follow-up of the CONSENSUS trial). Am J Cardiol 1990, 66:40D-45D. discussion 44D-5D.